Europe Insulin Syringe Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 111.88 Million |
| Market Size (2029) | USD 118.76 Million |
| CAGR (2024 - 2029) | 1.20 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Europe Insulin Syringe Market Analysis
The Europe Insulin Syringe Market size is estimated at USD 111.88 million in 2024, and is expected to reach USD 118.76 million by 2029, growing at a CAGR of 1.20% during the forecast period (2024-2029).
European countries are suffering from the burden of high diabetes expenditure due to its rising prevalence. In high-income countries, diabetes is one of the leading causes of cardiovascular diseases, blindness, kidney failure, and lower limb amputation. Technological advancements have increased over the period in Diabetes care devices for safer and more accurate administration of insulin. A needle and syringe are a common and cost-effective way for many people to take insulin. Approximately 10% of the total diabetes population is having type-1 diabetes and approximately out of this 10% of people only 80-90% use Insulin delivery devices but the usage of insulin is rising from time to time, even type-2 diabetes patients are using the insulin devices.
According to the IDF report, about 1 in 11 adults contain diabetes in Europe, accounting for approximately 61 million. These figures indicate that approximately 19.6% of global expenditure is spent on diabetes in Europe. Every year 21,600 children are added to the type-1 diabetic population pool. The European region witnessed an alarming increase in the prevalence of diabetes in recent years. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as oral anti-diabetic medication or ingestion of additional carbohydrates by monitoring their blood glucose levels.
According to IDF, to reduce the diabetes epidemic in the country, the Russian government needs to fully implement a National Diabetes Plan that establishes a state budget and guarantees diabetes care to all Russian citizens. Russia is working towards improving the reimbursement system for all aspects of diabetes care, limiting out-of-pocket payments, and preventing households from incurring catastrophic expenditures. Also, implementing a national screening program to improve the early identification of disturbed carbohydrate metabolism and creating a specialized diabetes health service under the Ministry of Health of the Russian Federation.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Europe Insulin Syringe Market Trends
Increasing diabetes prevalence
The diabetes population in the European region is expected to rise by more than 5% over the forecast period.
The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of insulin. Type-1 diabetic patients must check their blood glucose levels regularly, monitor their blood glucose levels, and adjust the insulin dosing accordingly. Insulin syringes are designed for self-injection and offer a reliable solution for insulin injection. An insulin syringe is made of three parts, which consist of a needle, a barrel, and a plunger. Needles are usually short and thin to reduce the pain of injection.
Various initiatives by the Government, such as the National Service Framework (NSF) program in the United Kingdom, are improving services by setting national standards to drive up service quality and tackle variations in care. The Association of British HealthTech Industries launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind.
Therefore, owing to the factors above, the studied market is anticipated to grow over the analysis period.
Russia holds the highest market share in the Europe Insulin Syringe Market in the current year
Russia holds the highest market share of more than 51% in the Europe Insulin Syringe Market in the current year.
According to Roscongress, Russia ranks fifth in the world regarding the number of patients with diabetes mellitus aged 20 to 79. The World Health Assembly Resolution recommends the integration of prevention and treatment of diabetes into primary health services, developing pathways for a substantial increase in access to insulin, promoting convergence and harmonizing regulatory requirements for diabetes medicines and technologies, and improving diabetes monitoring and surveillance.
Furthermore, it involves the WHO advising the Member States to ensure the uninterrupted treatment of people living with diabetes in humanitarian emergencies. This important milestone provides a global mandate for diabetes efforts for the next decade.
The roll-out of many new products, increasing international research collaborations in technology advancement, and increasing awareness about diabetes among people are some market opportunities for the players.
Europe Insulin Syringe Industry Overview
The Europe Insulin Syringe Market is moderately fragmented and driven by constant innovations by manufacturers such as Becton Dickinson, Terumo Corporation, and HMD Healthcare Ltd. It resorts to inorganic market strategies, such as mergers and acquisitions, to establish market dominance while adhering to organic growth strategies. It is evident from the R&D spending of these companies.
Europe Insulin Syringe Market Leaders
-
Becton Dickinson
-
Terumo Corporation
-
B. Braun Medical Inc.
-
Nipro Corporation
-
HMD Healthcare Ltd.
*Disclaimer: Major Players sorted in no particular order
Europe Insulin Syringe Market News
- November 2023: Terumo India launched new Insulin Syringe for diabetic patients who need daily injections to control their condition.
- October 2022: Becton, Dickinson, and Company and Biocorp signed an agreement to use connected technology to track adherence to self-administered drug therapies, like biologics. To support biopharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies will integrate Biocorp's Injay technology. It is a solution designed to capture and transmit injection events using Near Field Communication technology to the BD UltraSafe Plus Passive Needle Guard used with pre-fillable syringes.
- October 2022: Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation and manufacturer of primary container, injection, and infusion therapy devices, launched a ready-to-fill polymer syringe. The PLAJEX 2.25 mL with a tapered needle is specifically designed for challenging biotech products with a larger volume.
Europe Insulin Syringe Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
- 5.1 Insulin Syringe
-
5.2 Geography
- 5.2.1 United Kingdom
- 5.2.2 Germany
- 5.2.3 France
- 5.2.4 Russia
- 5.2.5 Spain
- 5.2.6 Italy
- 5.2.7 Rest of Europe
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
- 7.1.1 Becton Dickinson
- 7.1.2 Terumo Corporation
- 7.1.3 B. Braun Medical Inc.
- 7.1.4 Nipro Corporation
- 7.1.5 HMD Healthcare Ltd.
- 7.1.6 Cardinal Health
- *List Not Exhaustive
- 7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityEurope Insulin Syringe Industry Segmentation
Insulin syringes are used for self-injection and are available in multiple sizes to help deliver different insulin doses. The europe insulin syringe market is segmented into geography. The report offers the value (in USD) and volume (in units) for the above segments.
| Geography | United Kingdom |
| Germany | |
| France | |
| Russia | |
| Spain | |
| Italy | |
| Rest of Europe |
Europe Insulin Syringe Market Research FAQs
How big is the Europe Insulin Syringe Market?
The Europe Insulin Syringe Market size is expected to reach USD 111.88 million in 2024 and grow at a CAGR of 1.20% to reach USD 118.76 million by 2029.
What is the current Europe Insulin Syringe Market size?
In 2024, the Europe Insulin Syringe Market size is expected to reach USD 111.88 million.
Who are the key players in Europe Insulin Syringe Market?
Becton Dickinson, Terumo Corporation, B. Braun Medical Inc., Nipro Corporation and HMD Healthcare Ltd. are the major companies operating in the Europe Insulin Syringe Market.
What years does this Europe Insulin Syringe Market cover, and what was the market size in 2023?
In 2023, the Europe Insulin Syringe Market size was estimated at USD 110.54 million. The report covers the Europe Insulin Syringe Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Europe Insulin Syringe Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Europe Insulin Syringe Industry Report
Statistics for the 2024 Europe Insulin Syringe market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Insulin Syringe analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
